Navigation Links
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
Date:11/15/2009

SOUTH SAN FRANCISCO, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will hold a teleconference and webcast at 8:00 a.m. Eastern Time tomorrow, Monday, November 16, to discuss results from its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in patients with small cell lung cancer.

Conference Call and Webcast Information

To participate in the live call on Monday, November 16, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), please dial 866-816-1982 from the U.S. or 913-312-0857 for international callers. The Webcast can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also has conducted a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
2. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
3. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
4. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
5. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
6. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
7. Poniard Pharmaceuticals Receives Going Concern Qualification
8. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
9. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
10. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... RYE, New York (PRWEB) , ... February 23, 2017 , ... ... to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, ... the 30 clinical sites already enrolling children across the United States. , “There ...
(Date:2/23/2017)... CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... worries, or problems. He has also continued to spiritually evolve, which is the purpose ... published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide ...
(Date:2/22/2017)... Boca Raton, FL (PRWEB) , ... February 22, 2017 , ... ... made primarily from deer antler velvet, announced its products are coming soon to Amazon.com, ... by Clint and Shelley Thomson as a means to develop an effective natural treatment ...
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, the leading ... of hospitals, health information exchanges, physicians and patients, announced today that SES Direct ... Edition Health IT Module Certification via Drummond Group LLC, an Authorized Certification Body ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to fewer trips the emergency room, fewer hospital admissions, and better blood pressure ... Managed Care® (AJMC®) finds. The study can be found here . , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 ... report on the global market for intraoperative imaging, ... presently valued at US$ 513.9 million. According to ... keep surging on the grounds of increasing adoption ... the field of diagnostic imaging for neurosurgeries. The ...
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... MILFORD, Mass. , Feb. 23, 2017 /PRNewswire/ ... leading partner to global in vitro diagnostics manufacturers ... webinar series titled "Catalyzing Implementation of NGS-Based Tests" ... on March 30, 2017 at 11am Eastern Standard ... series is to highlight the need for improved ...
Breaking Medicine Technology: